百洋医药(301015.SZ)：上半年净利润1.63亿元 同比下降59.48%

Core Viewpoint - Baiyang Pharmaceutical (301015.SZ) reported a decline in both revenue and net profit for the first half of 2025, indicating potential challenges in its financial performance [1] Financial Performance - The company achieved operating revenue of 3.751 billion yuan, a year-on-year decrease of 6.02% [1] - The net profit attributable to shareholders was 163 million yuan, reflecting a significant year-on-year decline of 59.48% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 177 million yuan, down 52.16% year-on-year [1] - Basic earnings per share stood at 0.31 yuan [1]